1. Market Research
  2. > Pathology Industry

Prostate Cancer Industry, May 2016 Market Reports from Top Publishers

You might be interested in: Diagnostics, Molecular Diagnostic, Vaccine, Therapeutics, Healthcare, Biopsy Device, Cancer Diagnostic, Pharmaceutical, Biomarker, Therapy, Chemotherapy, Radiation Therapy, Biochip, Carotenoid, Diagnostic, Hormone, Oncology, Radiopharmaceutical, Transdermal Drug Delivery.


 
1-10 of 69 reports for Prostate Cancer

Purchase Reports From Reputable Market Research Publishers

Prostate Cancer Treatment Drugs Companies in China

Prostate Cancer Treatment Drugs Companies in China

  • $ 1 800
  • Industry report
  • March 2016
  • by Asia Market Information & Development Company

This study focuses on China’s Prostate Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions ...

Global Prostate Cancer Partnering 2010 to 2016

Global Prostate Cancer Partnering 2010 to 2016

  • $ 1 495
  • Industry report
  • May 2016
  • by Currentpartnering

The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. • ...

Prostate Cancer Treatment Drugs Industry Forecasts - China Focus

Prostate Cancer Treatment Drugs Industry Forecasts - China Focus

  • $ 1 000
  • Industry report
  • March 2016
  • by Asia Market Information & Development Company

This study focuses on China’s Prostate Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing ...

Prostate Cancer Treatment Drugs Markets in China

Prostate Cancer Treatment Drugs Markets in China

  • $ 4 000
  • Industry report
  • March 2016
  • by Asia Market Information & Development Company

China's demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Prostate Cancer: Update Bulletin [Feb 2016]

Prostate Cancer: Update Bulletin [Feb 2016]

  • $ 1 040
  • Industry report
  • February 2016
  • by Firstword Pharma

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) ...

Prostate Cancer Drug Pipeline Update

Prostate Cancer Drug Pipeline Update

  • $ 3 375
  • Industry report
  • February 2016
  • by Bioseeker

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various ...

Prostate Cancer Drug Pathway Analyzer

Prostate Cancer Drug Pathway Analyzer

  • $ 3 375
  • Industry report
  • February 2016
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 493 targeted molecular therapies known to affect more than 255 specific intracellular signaling pathways ...

Target Atlas in Prostate Cancer: A Competitive Outlook

Target Atlas in Prostate Cancer: A Competitive Outlook

  • $ 3 375
  • Industry report
  • February 2016
  • by Bioseeker

Extra value: One year of free online updates included with this product "Target Atlas in Prostate Cancer: A Competitive Outlook" helps you to understand the complex world of commercial development in prostate ...

Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2 000
  • Industry report
  • January 2016
  • by Delve Insight

SUMMARY DelveInsight’s Report, “Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase ...

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2 000
  • Industry report
  • January 2016
  • by Delve Insight

SUMMARY DelveInsight’s Report, “Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, ...

About 3 600 reports for Prostate Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • December 2014
    174 pages
  • Prostate Cancer  

    Cancer  

    Urology  

  • United States  

View report >

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.